Orphan Drugs in MENA

In Market Access, Whitepapers by Freya Smale

Global Overview of Orphan Drug Market

Disease that have low prevalence rates are no less important than ones that have a higher incidence. Few of the countries have laws to determine the treatment and approach to orphan disease, and there are criteria that establish whether or not a disease can be classified in the first place. In Japan, a disease that affects less than 50,000 persons is an orphan disease. In US, this number is 200,000.1

Orphan drugs is a niche buster because they provide an ideal venue for companies to offset the lapsing patents and shrinking pipelines of blockbuster drugs. In such cases orphan drugs bring forth a new business model.1

The total number of disease categorized as orphan are stands at about 7,000 currently, with nearly 250 new disease being appended to this list annually. 1

Download the whitepaper as provided by Mesned now to find out more about:

  • Global Overview of Orphan Drug Market
  • Healthcare in KSA
  • Prevalence of Orphan Disease in MENA
  • Orphan Drug Market in KSA
  • Clinical Trial Opportunities

Get your copy here >

  1. Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018.

MPCC is joining us the World Orphan Drug Congress USA 2015. It’s not too late to join them – simply click the banner below to book.